Integrated Medicine for Sepsis: An RCT With Phenotyping (IMSEP-RCT)
Efficacy of Integrated Chinese and Western Medicine for Sepsis With Phenotypic Profiling: A Randomized Controlled Trial
This study aims to evaluate the clinical efficacy and safety of integrated traditional Chinese and Western medicine in the treatment of sepsis, explore its potential value in improving clinical outcomes, and provide high-quality clinical evidence for the integrated management of sepsis.In addition, blood samples will be collected for phenotyping and subsequent transcriptomic, proteomic, and metabolomic analyses.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of integrated traditional Chinese and Western medicine in patients with sepsis. By comparing primary and secondary clinical outcomes between the intervention and control groups, the study aims to assess the effects of integrated treatment on disease improvement and clinical outcomes in patients with sepsis and to provide high-quality evidence for its clinical application.Biospecimen Collection. Fasting venous blood samples will be collected at predefined time points for subsequent transcriptomic, proteomic, and metabolomic analyses.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Zhenzhen Feng, Doctor
- Telefonnummer: 15890658268
- E-mail: huxifzz@163.com
Studiesteder
-
-
Henan
-
Zhengzhou, Henan, Kina, 450000
- First Affiliated Hospital of Henan University of Traditional Chinese Medicine
-
Kontakt:
- Zhenzhen Feng, Doctor
- Telefonnummer: 15890658268
- E-mail: huxifzz@163.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥18 years and <80 years.
- Meeting the Sepsis-3.0 definition and diagnostic criteria for sepsis, with a Sequential Organ Failure Assessment (SOFA) score of 2-13.
- Patients with pulmonary infection or bloodstream infection.
- Meeting the diagnostic criteria for one of the following traditional Chinese medicine syndrome patterns: phlegm-heat obstructing the lung syndrome, exuberant heat-toxin syndrome, Yangming bowel excess syndrome, or stasis-toxin obstructing the collaterals syndrome.
- Written informed consent provided by the patient or the patient's legally authorized representative/family member.
Exclusion Criteria:
- Patients with trauma, including fractures, burns, hepatic rupture, splenic rupture, or other major traumatic injuries.
- Pregnant or breastfeeding women.
- Patients with severe underlying diseases, including unresectable malignancies, hematologic diseases, or human immunodeficiency virus (HIV) infection.
- Use of immunosuppressive therapy or receipt of organ transplantation within the previous 3 months.
- Severe hepatic or renal dysfunction, defined as a score ≥3 in the hepatic or renal component of the SOFA score.
- Participation in another interventional drug clinical trial within 1 month prior to enrollment.
- Known allergy or hypersensitivity to any of the study medications.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Standard Western Medicine Plus Syndrome-Differentiated Chinese Herbal Medicine
Participants will receive standard Western medical treatment for sepsis in combination with syndrome-differentiated Chinese herbal medicine according to the study protocol. |
Participants will receive standard Western medical treatment for sepsis plus syndrome-differentiated Chinese herbal medicine. The herbal formula will be prescribed according to the participant's traditional Chinese medicine syndrome pattern: Qinghua Formula for phlegm-heat obstructing the lung syndrome (including Scutellaria baicalensis, Fritillaria thunbergii, Gardenia jasminoides, and other herbs); Qingjie Formula for exuberant heat-toxin syndrome (including Lonicera japonica, Gardenia jasminoides, Forsythia suspensa, and other herbs); Tonghe Formula for Yangming bowel excess syndrome (including Rheum palmatum, Magnolia officinalis, processed Citrus aurantium, and other herbs); and Jiehua Formula for stasis-toxin obstructing the collaterals syndrome (including Bubalus bubalis Cornu, Lonicera japonica, Forsythia suspensa, and other herbs). |
|
Placebo komparator: Standard Western Medicine Plus Matching Placebo
Participants will receive standard Western medical treatment for sepsis in combination with a matching placebo of the syndrome-differentiated Chinese herbal medicine according to the study protocol. |
Participants will receive standard Western medical treatment for sepsis plus a matching placebo corresponding to the syndrome-differentiated Chinese herbal medicine. The placebo is prepared using 5% of the corresponding herbal formulation and is designed to match the Chinese herbal granules in appearance, weight, color, and odor. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
28-Day All-Cause Mortality
Tidsramme: Day 28 after enrollment
|
The proportion of participants who die from any cause within 28 days after enrollment. |
Day 28 after enrollment
|
|
Sequential Organ Failure Assessment (SOFA) Score
Tidsramme: Baseline (Day 0), Day 7, Day 14, and Day 28 after enrollment
|
The Sequential Organ Failure Assessment (SOFA) score will be used to assess dysfunction in six organ systems: respiratory, coagulation, hepatic, cardiovascular, central nervous system, and renal function. The total score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction. |
Baseline (Day 0), Day 7, Day 14, and Day 28 after enrollment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acute Physiology and Chronic Health Evaluation II (APACHE II) Score
Tidsramme: Baseline (Day 0), Day 7, Day 14, and Day 28 after enrollment
|
Disease severity will be assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. The total score ranges from 0 to 71, with higher scores indicating greater disease severity. |
Baseline (Day 0), Day 7, Day 14, and Day 28 after enrollment
|
|
Length of ICU Stay
Tidsramme: From ICU admission through hospital discharge or Day 28, whichever occurs first
|
The duration of ICU stay will be calculated in days from ICU admission to the first discharge from the ICU. For participants who are readmitted to the ICU, ICU readmission and the cumulative duration of ICU stay will also be recorded. |
From ICU admission through hospital discharge or Day 28, whichever occurs first
|
|
Ventilator-Free Days Within 28 Days
Tidsramme: From enrollment through Day 28
|
The number of days during the first 28 days after enrollment that a participant is alive and free from invasive mechanical ventilation will be calculated. |
From enrollment through Day 28
|
|
ICU-Free Days Within 28 Days
Tidsramme: From enrollment through Day 28
|
The number of days through Day 28 during which a participant is alive and remains outside the ICU after the first ICU discharge will be calculated. |
From enrollment through Day 28
|
|
Time to Sustained Resolution of Fever
Tidsramme: From enrollment through Day 28
|
The time from enrollment to normalization of body temperature sustained for more than 72 hours will be recorded. A transient reduction in body temperature following administration of antipyretic medication will not be considered sustained resolution of fever. |
From enrollment through Day 28
|
|
Duration of Antimicrobial Therapy
Tidsramme: From enrollment through hospital discharge or Day 28, whichever occurs first.
|
The cumulative duration of intravenous and/or oral antimicrobial therapy during hospitalization will be recorded in days. |
From enrollment through hospital discharge or Day 28, whichever occurs first.
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Jiansheng Li, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2026-Sepsis-RCT
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .